JP2015509933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509933A5 JP2015509933A5 JP2014556735A JP2014556735A JP2015509933A5 JP 2015509933 A5 JP2015509933 A5 JP 2015509933A5 JP 2014556735 A JP2014556735 A JP 2014556735A JP 2014556735 A JP2014556735 A JP 2014556735A JP 2015509933 A5 JP2015509933 A5 JP 2015509933A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- eye
- item
- ear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 6
- 239000003889 eye drop Substances 0.000 claims description 6
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims description 4
- 229920002907 Guar gum Polymers 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical group C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
- 230000001387 anti-histamine Effects 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 229960000325 emedastine Drugs 0.000 claims description 4
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 claims description 4
- 229960002154 guar gum Drugs 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- 239000000665 guar gum Substances 0.000 claims description 4
- 229960004114 olopatadine Drugs 0.000 claims description 4
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical group Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229960004677 emedastine difumarate Drugs 0.000 claims description 2
- FWLKKPKZQYVAFR-SPIKMXEPSA-N emedastine difumarate Chemical group OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 FWLKKPKZQYVAFR-SPIKMXEPSA-N 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- -1 hydroxypropyl Chemical group 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 description 2
- 239000003221 ear drop Substances 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597416P | 2012-02-10 | 2012-02-10 | |
| US61/597,416 | 2012-02-10 | ||
| PCT/US2013/025376 WO2013119974A1 (en) | 2012-02-10 | 2013-02-08 | Aqueous pharmaceutical composition with enhanced stability |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509933A JP2015509933A (ja) | 2015-04-02 |
| JP2015509933A5 true JP2015509933A5 (https=) | 2016-03-17 |
| JP6180443B2 JP6180443B2 (ja) | 2017-08-16 |
Family
ID=47750831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556735A Expired - Fee Related JP6180443B2 (ja) | 2012-02-10 | 2013-02-08 | 安定性が強化された水性医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20130210812A1 (https=) |
| EP (1) | EP2811979B1 (https=) |
| JP (1) | JP6180443B2 (https=) |
| KR (1) | KR102047954B1 (https=) |
| CN (1) | CN104168885A (https=) |
| AU (1) | AU2013216847B2 (https=) |
| BR (1) | BR112014019742A8 (https=) |
| CA (1) | CA2864165A1 (https=) |
| MX (1) | MX356050B (https=) |
| RU (1) | RU2014136715A (https=) |
| TW (1) | TW201336527A (https=) |
| WO (1) | WO2013119974A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10744153B1 (en) * | 2019-07-01 | 2020-08-18 | Cloudbreak Therapeutics Llc | Compositions and methods for treating meibomian gland dysfunction |
| WO2025137749A1 (pt) * | 2023-12-27 | 2025-07-03 | Eurofarma Laboratórios S.A. | Processo de solubilização de olopatadina e seu uso |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4027020A (en) | 1974-10-29 | 1977-05-31 | Millmaster Onyx Corporation | Randomly terminated capped polymers |
| US3931319A (en) | 1974-10-29 | 1976-01-06 | Millmaster Onyx Corporation | Capped polymers |
| US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4407791A (en) | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| US4836986A (en) | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| JPS6310784A (ja) | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | 抗アレルギー剤 |
| US5037647A (en) | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
| US5145643A (en) | 1990-01-05 | 1992-09-08 | Allergan, Inc. | Nonoxidative ophthalmic compositions and methods for preserving and using same |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5300287A (en) | 1992-11-04 | 1994-04-05 | Alcon Laboratories, Inc. | Polymeric antimicrobials and their use in pharmaceutical compositions |
| GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP0889056B1 (en) | 1997-07-01 | 2006-04-12 | Pfizer Products Inc. | Process for making a cyclodextrin |
| DE69839355T2 (de) * | 1997-07-29 | 2009-06-04 | Alcon Laboratories, Inc., Fort Worth | Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat |
| US6375973B2 (en) * | 2000-01-25 | 2002-04-23 | Alcon Universal Ltd. | Ophthalmic anti-allergy compositions suitable for use with contact lenses |
| MXPA04008171A (es) * | 2002-02-22 | 2004-11-26 | Pharmacia Corp | Formulacion oftalmica con sistema de goma. |
| US20040198828A1 (en) * | 2003-01-17 | 2004-10-07 | Abelson Mark B. | Combinational use of long-acting and short-acting anti-histamines for ocular allergies |
| WO2008015695A2 (en) * | 2006-05-15 | 2008-02-07 | Sun Pharmaceutical Industries Limited | Inclusion complex of olopatadine and cyclodextrin |
| TWI434926B (zh) | 2006-12-11 | 2014-04-21 | Alcon Res Ltd | 眼用組成物中聚氧化乙烯-聚氧化丁烯（ｐｅｏ-ｐｂｏ）嵌段共聚物之使用 |
| PT2114367E (pt) * | 2007-02-07 | 2016-02-01 | Novartis Ag | Formulações de olopatadina para administração nasal tópica |
| ZA200904917B (en) * | 2007-02-09 | 2010-09-29 | Alcon Inc | Ophthalmic compositions containing a synergistic combination of three polymers |
| AR066901A1 (es) * | 2007-05-18 | 2009-09-23 | Alcon Mfg Ltd | Composiciones fodfolipidicas para elcuidado de lentes de contacto y conservacion de composiciones farmaceuticas |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| EP2393837A1 (en) | 2009-02-05 | 2011-12-14 | Alcon Research, Ltd. | Process for purifying guar |
| PH12012501111A1 (en) * | 2009-12-03 | 2016-09-09 | Novartis Ag | Carboxyvinyl polymer-containing nanoparticles suspensions |
| TWI478730B (zh) * | 2009-12-03 | 2015-04-01 | Alcon Res Ltd | 眼科乳劑 |
| CA2798069C (en) * | 2010-05-05 | 2016-07-05 | Howard Allen Ketelson | Stabilized ophthalmic galactomannan formulations |
| WO2011141929A2 (en) * | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Aqueous pharmaceutical compositions of fluticasone and olopatadine |
| TWI544922B (zh) * | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物 |
-
2013
- 2013-02-04 TW TW102104183A patent/TW201336527A/zh unknown
- 2013-02-08 BR BR112014019742A patent/BR112014019742A8/pt not_active IP Right Cessation
- 2013-02-08 WO PCT/US2013/025376 patent/WO2013119974A1/en not_active Ceased
- 2013-02-08 JP JP2014556735A patent/JP6180443B2/ja not_active Expired - Fee Related
- 2013-02-08 US US13/763,023 patent/US20130210812A1/en not_active Abandoned
- 2013-02-08 AU AU2013216847A patent/AU2013216847B2/en not_active Ceased
- 2013-02-08 RU RU2014136715A patent/RU2014136715A/ru not_active Application Discontinuation
- 2013-02-08 CN CN201380014179.XA patent/CN104168885A/zh active Pending
- 2013-02-08 MX MX2014009573A patent/MX356050B/es active IP Right Grant
- 2013-02-08 CA CA2864165A patent/CA2864165A1/en not_active Abandoned
- 2013-02-08 KR KR1020147024529A patent/KR102047954B1/ko not_active Expired - Fee Related
- 2013-02-08 EP EP13706360.8A patent/EP2811979B1/en not_active Not-in-force
-
2014
- 2014-08-25 US US14/468,243 patent/US20140364422A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124917T1 (el) | Παρασκευη στερεων συμπλοκων κυκλοδεξtρινης για παραδοση οφθαλμικου δραστικου φαρμακευτικου συστατικου | |
| MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| RU2013140423A (ru) | Офтальмологическая композиция с высокой концентрацией олопатадина | |
| CO6300926A2 (es) | Composicion dentifrica que contiene un hidrocoloide, un polisacarido, un copolimero y una fuente de ion de fluoruro | |
| HK1216319A1 (zh) | 无水的水凝胶组合物 | |
| BR112018010234A2 (pt) | spray formador de película tópica | |
| BRPI0416613A (pt) | composição e forma de dosagem compreendendo uma molécula anfifìlica como um veìculo de suspensão | |
| MX2022008277A (es) | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. | |
| WO2010065730A3 (en) | Pharmaceutical suspension | |
| WO2018106108A8 (en) | Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain | |
| SA519400913B1 (ar) | تركيبة موضعية لتعزيز إلتئام الجروح | |
| JP2015007136A5 (https=) | ||
| WO2015001087A3 (en) | Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition | |
| CL2012001402A1 (es) | Composicion farmaceutica en suspension oftalmica acuosa de administracion topica que comprende polimero de carboxivinilo, galactomanana, borato, compuesto en nanoparticulas escasamente soluble, agentes para ajustar ph y tonicidad, conservante y quelante; metodo para tratar trastornos oftalmicos, metodo para mantener viscosidad. | |
| MX382580B (es) | Formulaciones de liberación inmediata disuasivas de abuso que comprenden polisacáridos no celulósicos. | |
| CY1121841T1 (el) | Τοπικη αντιμυκητιασικη συνθεση για τη θεραπεια της ονυχομυκητιασης | |
| MX370898B (es) | Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
| ZA201807446B (en) | Improved drug formulations | |
| JP2015509933A5 (https=) | ||
| AR065342A1 (es) | Composiciones farmaceuticas que contienen fumarato de quetiapina | |
| JOP20170148A1 (ar) | مثبطات Wnt لعلاج التليف | |
| MX381932B (es) | Composicion intranasal que comprende betahistina. | |
| EA201200249A1 (ru) | Прасугрел в некристаллической форме и содержащая его фармацевтическая композиция | |
| GEP201606577B (en) | Nasal pharmaceutical formulation | |
| RU2014136715A (ru) | Водная фармацевтическая композиция с улучшенной стабильностью |